Lisata Therapeutics Inc (NASDAQ:LSTA) chief medical officer Dr Kristen Buck discussed with Proactive a promising collaboration between the company and the University of Cincinnati aimed at investigating an endometriosis treatment.
Dr Buck highlighted Certepetide, Lisata’s novel cyclic peptide therapeutic that targets integrins and neuropilin receptors, which are notably elevated in both solid tumors and endometriosis.
This project uses a mouse model developed by the University of Cincinnati to investigate how combining Certepetide with the anti-VEGF drug bevacizumab (Avastin) affects the reduction of endometrial lesions and related pain.
Proactive: Excited to talk to you about a recent news release from Lisata Therapeutics. It highlights a new partnership with the University of Cincinnati. We’ll get into the details of that shortly, but first, could you tell us more about Certepetide?
Kristen Buck: Sure. Certepetide is a unique asset—a cyclic nine-amino-acid peptide that selectively targets integrins and neuropilin receptors, which are often upregulated in solid tumors. Essentially, Certepetide enhances …